Answers are grounded in this paper and cite their sources.
Demonstrates the use of gene therapy in mouse models of Gaucher disease, indicating its potential for treatment.
Gaucher disease, the result of inherited deficiency of glucocerebrosidase, is the most common lysosomal storage disease. No naturally occurring animal models are available for study of its pathophysiology or the development of new therapeutic strategies such as gene therapy. We describe an approach to gene targeting in embryonic stem cells to “knock out” glucocerebrosidase activity and generate a mouse line having the phenotype of severely affected infants with type 2 Gaucher disease. We also discuss an experiment in gene therapy using lethally irradiated mice that are reconstituted with murine fetal liver hematopoietic cells transduced with retrovirus encoding human glucocerebrosidase. Analyses of these animals show production of active human glucocerebrosidase in lysosomes of macrophages for at least 12 months after transplantation.
No takes yet. Share an insight, caveat, or question.
McKinney et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: